Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prasugrel vs Ticagrelor in CHIP Patients (E5TION)
NCT04734353Phase 4Unknown
- Sponsor
- Gyeongsang National University Hospital
- Start
- Jan 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of prasugrel and ticagrelor in coronary artery disease (CAD) (2 arms), sponsored by Gyeongsang National University Hospital. Primary endpoint: Major bleeding and adherence to DAPT regimen at 1 year. Status: unknown.
02
Drugs
prasugrelticagrelor
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT04734353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04734353.